{"id":745661,"date":"2018-10-04T05:45:00","date_gmt":"2018-10-04T05:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/"},"modified":"2025-11-07T01:27:01","modified_gmt":"2025-11-07T06:27:01","slug":"mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/","title":{"rendered":"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens"},"content":{"rendered":"<p class=\"bwalignc\">       New Data on Patients Who Were Virologically Suppressed Switching to        DELSTRIGO to be Presented as Late-Breaker Oral Presentation at IDWeek        2018     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the first presentation of data from the Phase 3<br \/>\n      DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO\u2122, a<br \/>\n      once-daily fixed-dose combination tablet of doravirine (100 mg),<br \/>\n      lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300<br \/>\n      mg), in adults with HIV-1 infection who demonstrated virological<br \/>\n      suppression for at least six months on a stable antiretroviral treatment<br \/>\n      regimen. The study met its primary endpoint of non-inferior efficacy as<br \/>\n      measured by the proportion of participants who switched to DELSTRIGO and<br \/>\n      had plasma HIV-1 RNA levels &lt;50 copies\/mL at Week 48 compared to the<br \/>\n      proportion of participants who continued on their baseline regimen and<br \/>\n      had HIV-1 RNA levels &lt;50 copies\/mL at Week 24. These study results will<br \/>\n      be presented today as a late-breaking oral presentation at <a href=\"https:\/\/idweek.org\/\" rel=\"nofollow\"><br \/>\n<b>IDWeek<br \/>\n      2018<\/b><br \/>\n<\/a> taking place Oct. 3-7, 2018, in San Francisco.\n    <\/p>\n<p>\n      \u201cThese data build on the existing clinical profile of DELSTRIGO as seen<br \/>\n      in treatment-na\u00efve patients, and suggests its potential to address a<br \/>\n      broader population,\u201d said Dr. Princy Kumar, Chief, Division of<br \/>\n      Infectious Diseases and Tropical Medicine at MedStar Georgetown<br \/>\n      University Hospital and Professor of Medicine and Microbiology,<br \/>\n      Georgetown University School of Medicine, Washington, D.C. \u201cData from<br \/>\n      this trial support another possible future option for people living with<br \/>\n      HIV, many of whom may require a change to a different treatment regimen.\u201d\n    <\/p>\n<p>\n      <b>Data from DRIVE-SHIFT<\/b>\n    <\/p>\n<p>\n      In the DRIVE-SHIFT study, 670 participants who demonstrated virological<br \/>\n      suppression (undetectable HIV-1 RNA) on an antiretroviral regimen for at<br \/>\n      least six months were randomized to begin treatment with DELSTRIGO<br \/>\n      (doravirine\/3TC\/TDF) immediately on Day 1 (immediate switch group, ISG;<br \/>\n      N=447) or after 24 weeks (delayed switch group, DSG; N=223). The primary<br \/>\n      endpoint was the proportion of participants with HIV-1 RNA &lt;50<br \/>\n      copies\/mL, with the primary comparison between the DELSTRIGO ISG at Week<br \/>\n      48 and baseline regimen DSG at Week 24, and a secondary comparison<br \/>\n      between the DELSTRIGO ISG and baseline regimen DSG at Week 24.\n    <\/p>\n<p>\n      In the study, DELSTRIGO-receiving participants in the ISG maintained<br \/>\n      virologic control at the 48-week timepoint:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        90.8 percent (406\/447) of participants who switched to DELSTRIGO on<br \/>\n        Day 1 (ISG) had HIV-1 RNA &lt;50 copies\/mL at Week 48; in comparison,<br \/>\n        94.6 percent (211\/223) of participants who continued on their baseline<br \/>\n        regimen (DSG) had HIV-1 RNA &lt;50 copies\/mL at Week 24 (treatment<br \/>\n        difference: -3.8%, 95% confidence interval: -7.9, 0.3).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        1.6 percent in the DELSTRIGO ISG group had HIV-1 RNA \u226550 copies\/mL at<br \/>\n        Week 48 compared to 1.8 percent in the baseline regimen DSG group at<br \/>\n        Week 24 (treatment difference: -0.2%, 95% confidence interval: -2.5,<br \/>\n        2.1).\n      <\/li>\n<\/ul>\n<p>\n      Secondary comparisons were also made at Week 24 for both treatment<br \/>\n      groups. DELSTRIGO-receiving participants in the ISG also maintained<br \/>\n      virologic control at this earlier (Week 24) timepoint:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        93.7 percent (419\/447) of participants who switched to DELSTRIGO on<br \/>\n        Day 1 (ISG) had HIV-1 RNA &lt;50 copies\/mL, compared with 94.6 percent<br \/>\n        (211\/223) of those who continued on their baseline regimen (DSG)<br \/>\n        (treatment difference: -0.9%; 95% confidence interval: -4.7, 3.0).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        1.8 percent in both treatment groups had HIV-1 RNA \u226550 copies\/mL at<br \/>\n        Week 24 (treatment difference: 0.0%; 95% confidence interval: -2.3,<br \/>\n        2.3).\n      <\/li>\n<\/ul>\n<p>\n      No genotypic or phenotypic resistance to any study drug was observed in<br \/>\n      participants taking DELSTRIGO through 48 weeks of treatment.\n    <\/p>\n<p>\n      At Week 24, participants who switched to DELSTRIGO on Day 1 showed<br \/>\n      statistically significant decreases in fasting LDL-cholesterol (LDL-C)<br \/>\n      and non-HDL-cholesterol (non-HDL-C) compared to those who continued on a<br \/>\n      boosted protease inhibitor regimen (LDL-C: -16.5 mg\/dL vs. -1.9 mg\/dL,<br \/>\n      treatment difference: -14.7, 95% confidence interval: -18.9, -10.4,<br \/>\n      p&lt;0.0001; non-HDL-C: -24.7 mg\/dL vs. -1.3 mg\/dL, treatment difference:<br \/>\n      -23.0, 95% confidence interval: -28.0, -18.1, p&lt;0.0001). At this<br \/>\n      timepoint, DELSTRIGO (doravirine\/3TC\/TDF) also showed decreases in<br \/>\n      cholesterol and triglyceride levels (cholesterol: -26.2 mg\/dL vs. 0.5<br \/>\n      mg\/dL, treatment difference: -25.8, 95% confidence interval: -31.0,<br \/>\n      -20.7; triglycerides: -43.2 mg\/dL vs. 0.9 mg\/dL, treatment difference:<br \/>\n      -42.9, 95% confidence interval: -59.1, -26.7).\n    <\/p>\n<p>\n      The most common adverse events (&gt;5% incidence in any group) in the<br \/>\n      DELSTRIGO ISG group through Week 24, the baseline regimen DSG group<br \/>\n      through Week 24, and the DSG group after the delayed switch to DELSTRIGO<br \/>\n      (Week 24 to Week 48) were nasopharyngitis (7.4%; 5.4%; 4.3%,<br \/>\n      respectively) and headache (6.5%; 2.2%; 6.7%, respectively). The most<br \/>\n      common drug-related adverse event (&gt;2% incidence in any group) was<br \/>\n      headache (1.6%; 0.4%; 2.4%, respectively). The rates of discontinuation<br \/>\n      of therapy due to adverse events through Week 24 were 2.5% in the<br \/>\n      DELSTRIGO ISG group and 0.4% in the baseline regimen DSG group.\n    <\/p>\n<p>\n      \u201cMerck\u2019s dedication over the past several decades to improving HIV<br \/>\n      treatment and care has always been focused on addressing unmet needs.<br \/>\n      People living with HIV need new treatment options,\u201d said Dr. George<br \/>\n      Hanna, vice president and therapeutic area head of infectious diseases,<br \/>\n      global clinical development, Merck Research Laboratories. \u201cThe data from<br \/>\n      DRIVE-SHIFT suggest the clinical potential of DELSTRIGO to serve as a<br \/>\n      new fixed-dose combination option for those considering a change in<br \/>\n      their HIV antiretroviral treatment regimen.\u201d\n    <\/p>\n<p>\n      <b>About DRIVE-SHIFT<\/b>\n    <\/p>\n<p>\n      DRIVE-SHIFT is a Phase 3 multicenter, open-label, randomized,<br \/>\n      active-controlled, non-inferiority clinical trial evaluating a switch to<br \/>\n      DELSTRIGO compared with continuation of current therapy in adults with<br \/>\n      HIV-1 infection who were virologically suppressed (undetectable plasma<br \/>\n      HIV-1 RNA levels &lt;40 copies\/mL) for at least six months on a stable<br \/>\n      regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus<br \/>\n      a boosted protease inhibitor, boosted elvitegravir, or NNRTI.<br \/>\n      Participants with screening HIV-1 RNA &lt;40 copies\/mL, no history of<br \/>\n      virologic failure on any regimen, and no resistance to DELSTRIGO were<br \/>\n      randomized (2:1) to start DELSTRIGO on Day 1 (ISG) or after 24 weeks<br \/>\n      (DSG). The primary endpoint was the proportion of participants with<br \/>\n      HIV-1 RNA &lt;50 copies\/mL, with the primary comparison between the<br \/>\n      DELSTRIGO ISG at Week 48 and baseline regimen DSG at Week 24 and a<br \/>\n      secondary comparison between the treatment groups at Week 24. For<br \/>\n      further information regarding DRIVE-SHIFT please visit <a href=\"https:\/\/www.clinicaltrials.gov\/\" rel=\"nofollow\">www.clinicaltrials.gov<\/a><br \/>\n      clinical trial registry number NCT02397096.\n    <\/p>\n<p>\n      On Aug. 30, 2018, DELSTRIGO (doravirine\/3TC\/TDF) was approved by the<br \/>\n      U.S. Food and Drug Administration for the treatment of HIV-1 infection<br \/>\n      in adult patients with no prior antiretroviral treatment experience and<br \/>\n      is administered orally once daily with or without food. In the U.S.,<br \/>\n      DELSTRIGO contains a boxed warning regarding post-treatment acute<br \/>\n      exacerbation of hepatitis B (HBV) infection. DELSTRIGO does not cure<br \/>\n      HIV-1 infection or AIDS. On Sept. 20, 2018, the Committee for Medicinal<br \/>\n      Products for Human Use (CHMP) of the European Medicines Agency (EMA)<br \/>\n      adopted a positive opinion recommending granting of marketing<br \/>\n      authorization for DELSTRIGO.\n    <\/p>\n<p>\n      <b>Selected Safety Information about DELSTRIGO (doravirine\/3TC\/TDF)<\/b>\n    <\/p>\n<p>\n      <i>Warning: Post treatment Acute Exacerbation of Hepatitis B (HBV)<\/i>\n    <\/p>\n<p>\n      All patients with HIV-1 should be tested for the presence of HBV before<br \/>\n      initiating antiretroviral therapy. Severe acute exacerbations of HBV<br \/>\n      have been reported in patients who are coinfected with HIV-1 and HBV and<br \/>\n      have discontinued products containing 3TC or TDF, which are components<br \/>\n      of DELSTRIGO. Patients coinfected with HIV-1 and HBV who discontinue<br \/>\n      DELSTRIGO should be monitored with both clinical and laboratory<br \/>\n      follow-up for at least several months after stopping DELSTRIGO. If<br \/>\n      appropriate, initiation of anti-HBV therapy may be warranted.\n    <\/p>\n<p>\n      DELSTRIGO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (<i>Hypericum perforatum<\/i>)),<br \/>\n      as significant decreases in doravirine plasma concentrations may occur,<br \/>\n      which may decrease the effectiveness of DELSTRIGO. DELSTRIGO is<br \/>\n      contraindicated in patients with a previous hypersensitivity reaction to<br \/>\n      3TC.\n    <\/p>\n<p>\n      Renal impairment, including cases of acute renal failure and Fanconi<br \/>\n      syndrome, have been reported with the use of TDF. DELSTRIGO should be<br \/>\n      avoided with concurrent or recent use of a nephrotoxic agent, as cases<br \/>\n      of acute renal failure after initiation of high-dose or multiple NSAIDs<br \/>\n      have been reported in patients with risk factors for renal dysfunction<br \/>\n      who appeared stable on TDF.\n    <\/p>\n<p>\n      Prior to or when initiating DELSTRIGO, and during treatment, assess<br \/>\n      serum creatinine, estimated creatinine clearance, urine glucose and<br \/>\n      urine protein in all patients. In patients with chronic kidney disease,<br \/>\n      also assess serum phosphorus. Discontinue DELSTRIGO in patients who<br \/>\n      develop clinically significant decreases in renal function or evidence<br \/>\n      of Fanconi syndrome. Discontinue DELSTRIGO (doravirine\/3TC\/TDF) if<br \/>\n      estimated creatinine clearance declines below 50 mL\/min.\n    <\/p>\n<p>\n      In clinical trials in HIV-1 infected adults, TDF was associated with<br \/>\n      slightly greater decreases in bone mineral density (BMD) and increases<br \/>\n      in biochemical markers of bone metabolism. Serum parathyroid hormone<br \/>\n      levels and 1,25 vitamin D levels were also higher. Cases of osteomalacia<br \/>\n      associated with proximal renal tubulopathy have been reported with the<br \/>\n      use of TDF.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Because DELSTRIGO is a complete<br \/>\n      regimen, co-administration with other antiretroviral medications for the<br \/>\n      treatment of HIV-1 infection is not recommended.\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.\n    <\/p>\n<p>\n      If co-administered with rifabutin, take one tablet of DELSTRIGO once<br \/>\n      daily, followed by one tablet of doravirine (PIFELTRO) approximately 12<br \/>\n      hours after the dose of DELSTRIGO. The most common adverse reactions<br \/>\n      with DELSTRIGO (incidence \u22655%, all intensities) were dizziness (7%),<br \/>\n      nausea (5%) and abnormal dreams (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to DELSTRIGO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      DELSTRIGO due to the potential for HIV-1 transmission. Because DELSTRIGO<br \/>\n      is a fixed-dose combination tablet and the components cannot be altered,<br \/>\n      it is not recommended in patients with estimated creatinine clearance<br \/>\n      less than 50 mL\/min.\n    <\/p>\n<p>\n      <b>Our Commitment to HIV<\/b>\n    <\/p>\n<p>\n      For more than 30 years, Merck has been committed to scientific research<br \/>\n      and discovery in HIV and we continue to be driven by the conviction that<br \/>\n      more medical advances are still to come. Our focus is on pursuing<br \/>\n      research that addresses unmet medical needs and helps people living with<br \/>\n      HIV and their communities. We remain committed to working hand-in-hand<br \/>\n      with our partners in the global HIV community to address the complex<br \/>\n      challenges to continuing progress.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola.\n    <\/p>\n<p>\n      For more information, visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a>&nbsp;and&nbsp;connect<br \/>\n      with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, NJ, USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      at:&nbsp;<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <b>Patient Information for DELSTRIGO (doravirine\/3TC\/TDF) at:&nbsp;<\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20181004005290r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       For Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Sarra        S. Herzog, 201-669-6570<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Michael DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg), in adults with HIV-1 infection who demonstrated virological suppression for at least six months on a stable antiretroviral treatment regimen. The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels &lt;50 copies\/mL at Week 48 compared to the proportion of participants who continued on their baseline regimen and had HIV-1 RNA levels &lt;50 copies\/mL at Week 24. These study results will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cThese data build on the existing clinical<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745661","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg), in adults with HIV-1 infection who demonstrated virological suppression for at least six months on a stable antiretroviral treatment regimen. The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels &lt;50 copies\/mL at Week 48 compared to the proportion of participants who continued on their baseline regimen and had HIV-1 RNA levels &lt;50 copies\/mL at Week 24. These study results will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cThese data build on the existing clinical\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\\\/\",\"name\":\"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-10-04T05:45:00+00:00\",\"dateModified\":\"2025-11-07T06:27:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \\\/ lamivudine \\\/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/","og_locale":"en_US","og_type":"article","og_title":"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from the Phase 3 DRIVE-SHIFT trial evaluating a switch of medication to DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg), in adults with HIV-1 infection who demonstrated virological suppression for at least six months on a stable antiretroviral treatment regimen. The study met its primary endpoint of non-inferior efficacy as measured by the proportion of participants who switched to DELSTRIGO and had plasma HIV-1 RNA levels &lt;50 copies\/mL at Week 48 compared to the proportion of participants who continued on their baseline regimen and had HIV-1 RNA levels &lt;50 copies\/mL at Week 24. These study results will be presented today as a late-breaking oral presentation at IDWeek 2018 taking place Oct. 3-7, 2018, in San Francisco. \u201cThese data build on the existing clinical","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:01+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/","name":"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-10-04T05:45:00+00:00","dateModified":"2025-11-07T06:27:01+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/mercks-hiv-therapy-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-meets-primary-efficacy-endpoint-in-phase-3-drive-shift-study-evaluating-switch-to-delstrigo-fro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck\u2019s HIV Therapy DELSTRIGO\u2122 (doravirine \/ lamivudine \/ tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9ff305bc-c47e-4449-a849-5be1a1c83b80","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Mercks-HIV-Therapy-DELSTRIGO-doravirine--lamivudine--tenofovir-disoproxil-fumarate-Meets-Primary-Efficacy-Endpoint-in-Phase-3-DRIVE-S-DMQAO.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745661\/revisions"}],"predecessor-version":[{"id":3675008,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745661\/revisions\/3675008"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745661"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}